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Abstract
Cervical cancer represents one of the major problems of health women worldwide, espe‐
cially in the developing countries. If discovered in its earliest stages, cervical cancer is 
successfully treatable; however, due to lack of proper implementation of screening pro‐
grams, the majority of cervical cancer patients are diagnosed in advanced stages, which 
dramatically influence their outcome. Almost a half of these patients will suffer recur‐
rence or metastasis in the following 2 years after therapy. If there are no immediate pros‐
pects in terms of developing new or more effective therapies, identifying new tools for 
early diagnosis, prognosis and treatment prediction remains a big challenge for cervical 
cancer. miRNAs have been validated to be key players in cell physiology, alterations in 
miRNA expression being associated with cancer progression and response to therapy. 
Cervical cancer studies have showed that alterations of miRNA expression can be identi‐
fied in tumor tissues, exfoliated cervical cells and patients serum and that their transcrip‐
tion pattern is regulated by the present HPV genotype. Furthermore, miRNAs have been 
associated with patients response to therapy, therefore suggesting their potential to be 
used as biomarkers for cervical cancer diagnosis, prognosis and treatment response.
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1. Introduction
With an incidence of over a half million new cases every year, cervical cancer still represents 
a major health problem for women worldwide. The last collected data from 2012 show that 
the incidence is not proportionally distributed, 84% of new cases (444,500 out of 527,600) 
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being recorded in developing countries and only 16% new cases in developed ones [1]. 
Consequently, the mortality rate is pretty similar, with 86.63% deaths (230,200 of 265,700) 
recorded in developing areas, compared with 13.47% deaths registered in developed ones.
This burden is related to the dis‐proportional implementation of screening programs (Pap 
smear and HPV tests), which allow the early detection of cervical precancerous and cancerous 
lesions that can be successfully treated surgically. Previous data revealed that cervical cancer 
control programs based on Pap test reduce the risk of cervical cancer with 25–36% [2]. To max‐
imize the screening effect, World Human Organization (WHO) recommended Pap test for 
women 30 years or older, considered at high risk for developing cervical cancer. Moreover, 
testing and following the patients with persistent high‐risk HPV infections could identify the 
early stages of cervical cancer.
Unfortunately, due to lack of proper implementation of screening programs in developing 
areas, the majority of cervical cancer patients are diagnosed in locally advanced stages (IIB–IIIB). 
Depending on the stage of the disease, the treatment includes radiotherapy concomitant with 
adjuvant or neoadjuvant chemotherapy, associated or not with surgery [3]. Nevertheless, the 
advanced stages will dramatically influence their response to the therapy, and almost a half of 
these patients will suffer recurrence or metastasis in the following 2 years after treatment.
In cervical cancer, as in the other cancers, the identification of new competitive drugs and new 
accurate biomarkers for diagnosis and prognosis is challenging. If there are no immediate 
prospects regarding developing new or more effective drug‐based therapies, identifying new 
tools for early diagnosis, prognosis or treatment predictions, has become a necessity.
The genomics revolution has uncovered new molecular data that advanced the characteriza‐
tion and the understanding of the complex regulatory signaling networks that drive cancer 
growth and development. Molecular findings related to both coding and non‐coding tran‐
scriptome were investigated in order to identify new cancer biomarkers, including in cervical 
cancer. Of these, non‐coding RNAs related to cell functionality, such as micro‐RNA (miRNA), 
have became important pieces of puzzle to characterize cervical cancer phenotype or to inves‐
tigate their involvement in prognosis and treatment response.
The subsequent chapter will present the existent data regarding the involvement of miRNAs 
in cervical carcinogenesis, including their synthesis, stability and specificity, as well as the 
role of HPVs infection in modulating host’s miRNAs expression. Furthermore, we will dis‐
cuss the latest updates on the miRNAs clinical applications as additional valuable markers for 
diagnosis, prognosis and treatment prediction in cervical cancer.
2. Micro‐RNAs
MiRNAs represent a class of non‐coding RNAs, evolutionary conserved between species, 
which negatively regulate gene expression at both transcriptional and post‐transcriptional 
levels, during normal and pathological conditions [4, 5]. Functional studies indicate that up 
to 60% of protein‐coding genes (PCGs) are regulated by miRNAs, which “gained” them the 
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name of “master modulators” of the human genome [6, 7]. An interesting aspect of miRNAs 
is that each miRNA can target up to 200 mRNAs on average or different miRNAs can target 
the same mRNA [8]. In physiological conditions, miRNAs play important roles in the modu‐
lation of many cellular processes and mechanisms such as angiogenesis, cell cycle regulation, 
differentiation, apoptosis, DNA repair or stress response. Subsequently, when alterations 
occur in their expression, miRNAs become key regulators of many diseases, including cancer. 
Several genetic and epigenetic events induce changes in miRNAs expression, including DNA 
amplifications or deletions that lead to gain or loss of miRNAs loci regions. Moreover, DNA 
mutations or SNPs (single nucleotide polymorphisms) inside of miRNAs coding genes could 
modify the miRNAs specificity by changing their structure [9]. Epigenetic modifications are 
related to hypermethylation of CpG islands of the transcriptional factors and promoters of 
miRNA‐coding genes resulting in silencing of these genes, leading to miRNAs expression 
alteration [10]. Croce’s group demonstrated for the first time an association of miRNAs with 
cancer, identifying deletion and down‐regulation of two miRNAs (miR‐15 and miR‐16) in 
13q14 LOH (Loss of Heterozygosity) of chronic lymphocytic leukemia [11]. The same group 
demonstrated that the majority of miRNAs genes are located in cancer‐associated genomic 
regions, considered genomic fragile sites [12]. Taking advantage of high‐throughput microar‐
ray technology, Calin et al. [13] demonstrated that genome‐wide miRNA profiling represents 
a reliable tool to characterize and investigate tumor phenotypes, deepening the understand‐
ing of the molecular mechanisms of cancer. Since 1993, when the first miRNAs were discov‐
ered, extensive research and tremendous efforts were put into identifying and characterizing 
new miRNAs. Due to the identification of growing numbers of miRNAs, a miRNA database 
was assembled, the miRBase Release 2.0 including 506 miRNA sequences from six organisms 
became firstly available in 2004 via web interface [14]. Currently, 26,654 entries from 223 spe‐
cies, including 2588 mature human miRNAs, have been deposited in the newest data from 
miRBase Release 21 (http://www.mirbase.org/).
2.1. Biogenesis of miRNA
It is estimated that only a small fraction (less than 2%) of the human genome is represented by 
coding DNA (exons from PCGs), while the rest of 98% include sequences of non‐coding DNA 
such as introns, non‐coding RNAs, regulatory DNA sequences, and other DNA sequences 
with unknown functions [15]. Non‐coding DNAs play important roles in controlling all steps 
of gene expression, when PCGs are transcribed into mRNAs and translated into proteins. The 
investigation of functions of non‐coding DNAs during the ENCODE (Encyclopedia of DNA 
Elements) project revealed new data related to how genetic information is converted into 
living cells and also the fact that almost 80% of human genome is activate in cell physiology 
[16]. Part of non‐coding RNAs, miRNAs represent the most studied components being widely 
accepted that they are major players in cell cycle dynamics, regardless of the physiological or 
pathological status.
Generally, almost all regions of the genome may encode miRNA. As much as 40% of miRNAs 
are located in intragenic regions, within the introns or even in the exons of the PCGs. The 
majority of the miRNAs (50%) are encoded by both intronic (40%) and exonic (10%) regions of 
non‐protein coding genes also known as non‐protein coding RNAs (npcRNAs) (Figure 1) [17].
The Role of miRNAs in Diagnosis, Prognosis and Treatment Prediction in Cervical Cancer
http://dx.doi.org/10.5772/68011
111
The miRNAs transcription starts in the nucleus being mediated by RNA polymerase II [18], 
but there is also some evidence that miRNAs could be transcribed by RNA polymerase III 
when are associated with Alu family repetitive elements [19]. The first miRNA transcripts 
(pri‐miRNAs) transcribed from DNA are long hairpin structures that include hundreds 
or thousands nucleotides. Upon recognition of a microprocessor complex, including RNA 
polymerase III Drosha and DGCR8 (DiGeorge syndrome critical region 8), pri‐miRNAs are 
processed into one or more smaller hairpins of about 70 nucleotides long called precursor 
Figure 1. The biogenesis of miRNAs. MiRNAs are transcribed from intra‐ and intergenic regions of DNA, from both 
PCGs and npcRNAs. The long hairpins structures (pri‐miRNA) transcribed from DNA are cleaved in pre‐miRNAs 
smaller transcripts (∼70 nucleotides long) by a microprocessor complex that includes Drosha and DGCR8 enzymes. 
After nuclear export through exportin 5, pre‐miRNAs are processed to mature miRNAs. One miRNA strand is loaded 
in RNA‐induced silencing complex (RISC) complex, while the other is degraded. RISC complex aligns by sequence 
complementarity to the target mRNA and negatively regulate their expression by degradation and/or translational 
repression.
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 miRNAs (pre‐miRNAs) [20]. Forward, pre‐miRNAs are exported from nucleus to the cyto‐
plasm by the nuclear export receptor exportin 5 [21]. After their export in cytoplasm, pre‐miR‐
NAs are processed by cytoplasmic RNA polymerase III Dicer to generate 21–23 nucleotides 
mature miRNA duplexes [22]. The miRNA strand with less stable paired 5′ end will be pref‐
erentially loaded into Argonaute 2 (AGO2) proteins that possess cleavage activity, while the 
other miRNA strand will be degraded [23]. The miRNA‐loaded AGO2 protein will be incor‐
porated into RNA‐induced silencing complex (RISC) that will target by sequence complemen‐
tarity to the 3′UTR of specific mRNA target, leading to mRNA degradation or translational 
repression.
2.2. MiRNAs in cancer
Non‐coding RNAs, especially miRNAs, have changed the sense of the “central dogma of 
molecular biology.” In accordance with central dogma of molecular biology, RNAs represent 
intermediary information in the genetic flow, by copying genetic information (transcription) 
from DNA and transform it (translation) to cellular effectors, the proteins:
 
DNA → transcription → mRNA → translation → Proteins 
                            ( the central dogma of molecular biology )  (1)
Following discovery and characterization of small non‐coding RNA, such as miRNAs, siR‐
NAs and piwi RNAs as well as long non‐coding RNAs and ultraconserved elements (UCEs), 
the central dogma of molecular biology has became more complex [24]. Actually, the genetic 
information from DNA is transcribed in both coding RNAs (mRNAs) and non‐coding RNAs 
(miRNAs, siRNAs, piwiRNAs, lncRNAs and ECEs). Furthermore, ncRNAs actively partici‐
pate both in the regulation of protein synthesis by regulation of the DNA transcription and 
mRNA translation as well as by regulating their expression by complex cross‐regulation [16] 
(Figure 2).
Figure 2. The new concept of the central dogma of molecular biology. The genetic information from DNA is transcribed 
(bold arrows) in both coding RNAs (mRNAs) and non‐coding RNAs (miRNAs, siRNAs, piwiRNAs, lncRNAs and 
ECEs), while the mRNA translation in their specific proteins includes complex regulations (regular arrows) performed 
by all type of ncRNAs.
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After their discovery, miRNAs have become a hot subject for many researchers worldwide, 
in the attempt to establish their role in cell functionality, especially in cancer. Croce’s lab was 
the first that established that miRNAs alteration can be associated with cancer [11], show‐
ing that miR‐15 and miR‐16 were deleted or down‐regulated in the majority of patients with 
chronic lymphocytic leukemia. Furthermore, they demonstrated that these miRNAs act as 
tumor suppressor genes, inducing apoptosis of leukemic tumor cells by negatively regula‐
tion of the expression of BCL2 oncogene (mRNA), which encodes a protein that blocks the 
apoptotic death [25]. The expression of both miR‐15 and miR‐16 was inversely correlated with 
Bcl2 expression, strengthening the hypothesis that miRNAs are post‐transcriptional nega‐
tive regulators their mRNA targets and can be successfully used to characterize malignant 
hematological tumors [13]. Immediately afterwards, miRNA profiling has quickly become 
an important tool to characterize tumor phenotype and identify specific miRNA biomarkers. 
MiRNAs were clearly related to cancer development by three landmark studies published in 
Nature. In one of these studies, Lu et al. [26] demonstrated that poorly differentiated tumors 
are successfully classified when miRNA profiling is used; moreover, miRNA profiling repre‐
sents better classifiers than mRNA profiling. In the second landmark study, He et al. [27] dem‐
onstrated that miR‐17‐92 cluster has an oncogenic potential, and its expression can modulate 
carcinogenesis in B‐cell lymphoma in synergy with c‐myc transcriptor factor. Although the 
mechanism of the oncogenic effect has not been fully elucidated, the authors suggested a 
decrease of apoptosis in these cells. The mechanisms that underlie the synergy between c‐myc 
and miR‐17‐19b overexpression in B‐cell lymphomas were demonstrated 10 years later by 
Mihailovich et al. [28] based on a comprehensive analysis integrating proteomics, transcrip‐
tomics and miRNAs prediction analysis. The third landmark study performed by O’Donnell 
et al. [29] demonstrated that the activity of E2F1 transcriptional factor can be controlled by 
two clusters of miRNAs (mir‐17 and mir‐106a) whose expression is activated by c‐myc onco‐
gene. After miRNAs were definitively linked to cancer development, a worldwide research 
effort has been made to characterize and establish the miRNAs roles in cancer.
Collectively, all previous data showed that miRNAs represent key ubiquitous players 
involved in cancer development. MiRNAs regulate molecular pathways involved in all cancer 
hallmarks such as self‐sufficiency in growth signals, indolence to antigrowth signals, evasion 
from apoptosis, limitless potential replicative, angiogenesis, invasion and metastasis, repro‐
gramming energy metabolism and evading immune destruction [30].
The growing miRNA profiling data, target prediction and data validation led to the develop‐
ment of specialized online miRNA databases that can be easily accessed in a user‐friendly 
manner. Until now, there are at least 14 online open‐access databases containing extensive 
information about miRNAs [31]. Some of these databases (SomammiR DB2.0) are useful to 
search for miRNAs somatic mutations and to predict their functional analysis based on these 
mutations, to identify miRNAs alterations involved in protein regulation (CancerNet) or to 
review the annotation changes for each miRNAs entry (miRbase Tracker). Additional data‐
bases focus on miRNAs roles in particular types of cancer such as head and neck and oral 
carcinomas (HNOCDB), endometrial (miREC), renal (Renal Cancer cell database), pancre‐
atic (Pancreatic Cancer Database), sarcoma (Sarcoma microRNA Expression Database) or 
breast cancers (OncomiRdbB). Certain miRNA databases such as canEvolve include recent 
 information from next‐generation sequencing (NGS) technology in different type of cancers, 
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healthy people and other pathologies, while miRCancer stores data about miRNAs in can‐
cers collected by data mining. Other miRNAs databases are focused on the role of miRNAs 
in diagnosis and overall survival (PROGmiR) and their presence in extracellular vesicles 
(miRandola) as well as their role in autophagy activation (AutomiRDB).
2.3. MiRNAs can function as oncogenes or tumor suppressor genes
It is well known that cancer is a disease characterized by abnormal cell grown caused by 
uncontrolled division of cells. Two main classes of genes such as proto‐oncogenes (ex KRAS, 
MYC, Her‐2/neu, EGFR) and tumor‐suppressor (ex RB, TP53, PTEN) are involved in the regu‐
lation of cell cycle in normal conditions.
When cancer occurs, multiple genetic and epigenetic alterations disrupt the normal function 
of these two classes of genes leading to their abnormal expression and therefore, uncontrolled 
cell division [32]. Cancer cells appear when proto‐oncogenes are converted in oncogenes 
by “gain of function,” and tumor‐suppressor genes are inactivated or deleted resulting in 
“loss of function.” From a functional perspective, the oncogenes and tumor suppresser genes 
expression can be modulated by miRNAs toward mRNA degradation or translational repres‐
sion. Many previous studies have shown that miRNAs play both oncogene (oncomiR) and 
tumor‐suppressor (tumor‐suppressor miRNAs, TS‐miRNAs) roles. By their up‐regulation, 
onco‐miRNAs negatively modulate the expression of tumor suppressor genes, while the 
down‐regulation of TS‐miRNAs will result in the absence of regulation or increased expres‐
sion of oncogenes. A selection of oncomiRs and tumor‐suppressor miRNAs, their mRNA tar‐
gets as well as the pathologies where they are involved are presented in Table 1.
OncomiR or/tumor 
suppressor miR 
(TS‐miR)
MiRNAs/
expression
Validated mRNA 
targets/regulation
miRNAs Function Pathologies 
associated with 
miRNAs alteration
Ref.
oncomiR miR‐21↑ BCL2↓
PTEN↓
PDCD4↓
BTG2↓
TPM1↓
Promote cell 
survival and 
proliferation by 
antiapoptotic 
effects
Overexpressed in 
a variety of human 
tumors including 
breast, melanoma, 
ovarian, head and 
neck, colon, prostate, 
lung, pancreas and 
cervix
[33–37]
oncomiR miR‐155↑ PTEN↓
BCL2↓
SOCS1↓
SOCS6↓
BLC6↓
Induces cell 
proliferation, 
differentiation 
and migration, as 
well as inhibits 
apoptosis
Up‐regulated in 
different cancers 
such as, breast, 
liver, hematological 
malignancies and 
cervix
[37–40]
oncomiR miR‐221/222↑ PTEN↓
TIMP3↓
p27Kip1↓
CDKN1C/p57↓
BBC3/PUMA↓
Promotes cell 
proliferation, 
regulate cell cycle 
phase distribution, 
and inhibits 
apoptosis
Overexpressed 
in glioblastomas, 
thyroid papillary 
carcinomas, breast 
cancer, glioma, 
hepatocellular 
carcinoma, and lung 
cancer
[41]
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MiR‐21, one of the most oncogenic miRNAs, is frequently overexpressed in many tumor types 
[33] including cervical cancer cells [34]. MiR‐21 can down‐regulate multiple tumor suppressor 
genes such as phosphatase and tensin homolog (PTEN), B‐cell lymphoma protein 2 (BCL2), 
programmed cell death 4 (PDCD4), BTG2 or tropomyosin 2 (TPM2), leading to cell survival, 
increased proliferation and decreased apoptosis [35, 36].
MiR‐155 is another oncomiR highly expressed in tumors, which negatively regulated multiple 
tumor suppressor genes such as PTEN, suppressor of cytokine signaling 1(SOCS1),  suppressor 
OncomiR or/tumor 
suppressor miR 
(TS‐miR)
MiRNAs/
expression
Validated mRNA 
targets/regulation
miRNAs Function Pathologies 
associated with 
miRNAs alteration
Ref.
oncomiR Cluster 
miR‐17‐92↑
PTEN↓
TGFBR2↓
SMAD2↓
SMAD4↓
P21↓
Promote 
tumorignesis, cell 
cycle progression, 
cell proliferation 
and survival
Up‐regulation 
in glioblastoma, 
lymphomas as well 
as thyroid, pancreas, 
colorectal, breast, 
lung, and stomach 
cancers
[44, 45]
TS‐miR miR‐221/222↓ c‐Kit↓ Inhibits of 
erythropoiesis
Loss in 
erythroblastic 
leukemia
[42]
TS‐miR Cluster 
miR‐17‐92↓
AIB1↑ Suppress 
proliferation
Down‐regulation in 
breast cancer
[46]
TS‐miR miR‐15a↓
miR16‐1↓
BCL2↑ Induces 
apoptosis, inhibits 
carcinogenesis
Deleted (loss) in 
chronic lymphocytic 
leukemia, prostate, 
breast and cervical 
cancers
[11, 47, 48]
TS‐miR miR‐34↓ CCDC↑
CDK4↑
CDK6↑
HMGB1
Wnt/β↑
Induces apoptosis 
and inhibits cell 
proliferation, 
invasion and 
metastasis
Down‐regulated 
in laryngeal, 
liver, pancreatic, 
colorectal, breast 
and cervical cancers
[50–52]
TS‐miR miR‐143↓ KRAS↑
MMP‐13↑
CD44v3↑
COX2↑
ERK5↑
Suppress 
proliferation, 
tumor 
development and 
proliferation, 
invasion and 
metastasis and 
induces apoptosis
Down‐regulated in 
prostate, bladder, 
colon, breast and 
cervical cancers
[53, 54]
TS‐miR miR‐145↓ ERG↑
FLI‐1↑
KRAS↑
MUC1↑
IRS‐1↑
VEGF‐A↑
Suppress cell 
growth tumor 
invasion, 
proliferation 
angiogenesis and 
promotes apoptosis
Down‐regulated 
in prostate, colon, 
breast, ovarian and 
cervical cancer
[55–57]
Table 1. Selection of oncomiRs and tumor suppressor miRNAs (TS‐miR), their mRNA targets, and the pathologies were 
they are involved.
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of cytokine signaling (SOCS6), and B‐cell CLL/lymphoma 6 (BCL6) [37–39]. In cervical cancer, 
high expression of miR‐155 is associated with poor prognosis [40].
Two highly homologous microRNAs, miR‐221 and miR‐222, are key miRNAs deregulated 
in many types of cancers, having a double role as oncogenes or tumor suppressors depend‐
ing on the cellular context and tumor type. In the majority of tumors where mir221/222 were 
identified, these act as oncomiRs by promoting cell proliferation, regulating cell cycle phase 
distribution, and inhibiting apoptosis. Their validated targets include several tumor suppres‐
sor genes such as PTEN, BCL2 binding component 3 (BBC3/PUMA) and TIMP metallopep‐
tidase inhibitor 3 (TIMP3) tumor suppressor genes [41]. Contrary, in erythroleukemic cells, 
mir‐221/222 has been showed to act as tumor‐suppressors, by down‐regulating proto‐onco‐
gene receptor tyrosine kinase (c‐Kit), leading to inhibition of erythropoiesis [42].
Similar with miR221/222, miR‐17‐92 cluster was validated for both oncogenic and tumor sup‐
pressive roles [43]. The oncogenic activity of miR‐17‐92 cluster is related to the negative modula‐
tion of PTEN tumor suppressor gene [44], and multiple components of TGFβ signaling pathway, 
including transcriptional modulators such as SMAD2/SMAD4 and CDKNIA (p21) which are 
involved in negative regulation of cell cycle progression [45]. The suppressor role of miR‐17‐92 
cluster was proved by its miR‐17‐5p member that negatively regulates the nuclear receptor 
coactivator 3 (NCOA3/AIB1), leading to decreased proliferation of breast cancer cells [46].
While some miRNAs promote carcinogenesis by their up‐regulation, several studies have 
shown that the majority of tumors present deletions of miRNAs tumor suppressor genes, due 
to the fact that they are located in or near fragile sites of cancer‐associated genomic regions, 
genomics rearrangements (chromosomal and/or genes) [12]. For example, the first cluster of 
tumor suppressor miRNAs (mir‐15a/miR‐16‐1) was related to deletion of 13q14.3 region in 
chronic lymphocytic leukemia. Calin et al. [11] demonstrated that the expression of BCL2 
oncoprotein (anti‐apoptotic regulator), target of mir‐15a/miR‐16‐1, is inversely correlated 
with these miRNAs. The role of miR‐15 and mir‐16 tumor suppressor genes was also demon‐
strated in prostate and breast cancer cells [47, 48] as well as in cervical cancers [49].
A component of TP53 tumor suppressor network, mir‐34a represents another tumor suppres‐
sor gene that regulates cell proliferation by targeting cyclin D1 (CCDC1), cyclin‐dependent 
kinase 4 (CDK4) and cyclin‐dependent kinase 6 (CDK6) proteins or Wnt/β‐catenin signaling 
pathway in laryngeal [50], breast [51] colon and cervical cancers [52].
Down‐regulation or loss of function of miRNA‐143 was identified in multiple cancers including 
cervical cancer, being associated with carcinogenesis and tumor progression [53]. Some impor‐
tant targets of miR‐143 include KRAS proto‐oncogene conducting cancer development, matrix 
metallopeptidase 13 (MMP‐13) with role in metastasis, cluster of differentiation 44v3 (CD44v3) 
involved in migration and invasion, cyclooxygenase 2 (COX2) supporting tumor metastasis by 
tumor proliferation, migration and epithelial‐mesenchymal transition (EMT) [54].
Tumor suppressor miR‐145 has important roles in the regulation of cell proliferation, and 
its loss or down‐regulation has been associated with development and progression as well 
as invasion and metastasis of different type of malignancies such as breast, ovarian, colon, 
prostate and cervical cancer [55, 56]. The mir‐145 targets include erythroblast transformation‐
specific (ETS) family of transcriptions factors (ERG),
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KRAS, fms‐related tyrosine kinase 1 (FLT1), mucin 1 (MUC1), vascular endothelial growth 
factor A (VEGFA) and insulin receptor substrate 1, involved in different pathways of tumor 
progression and metastasis [57].
3. High‐risk HPV infection modulates miRNA expression in cervical 
cancer
Human Papillomaviruses (HPVs) represent the most important risk factor for developing cer‐
vical cancer. Papillomaviruses are small (50–60 nm) DNA viruses, counting over 200 members 
that include more than 150 HPVs [58]. Depending on their type of infection, HPVs are divided 
into two subgroups: cutaneous, which infects cutaneous skin producing benign papillomas 
(warts), and mucosal, infecting mucosal epithelial cells, which provoke epithelial dysplasia 
and invasive carcinoma. Currently, 12 HPVs that include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 subtypes are confirmed oncogenic and referred to as high‐risk HPVs (HR‐HPVs) [59]. 
The infection and minimum 2 years persistence with HR‐HPVs is a prior condition of cervical 
cancers. As a result of the discovery that HR‐HPVs are causative agents of cervical cancer, 
Harald zur Hausen was awarded the Nobel Prize in 2008. Data from epidemiological studies 
revealed that HPV 16 and 18 subtypes are associated with the majority of cervical cancers [60]. 
Moreover, previous data showed that HPV detection increases during transition from precan‐
cerous lesions to cervical cancers. If in CIN1 (cervical intraepithelial neoplasia) characterized 
by low‐grade dysplasia, HPV is present in proportion of 50–70%, in middle dysplasia (CIN2), 
it increases to 85%, while in severe dysplasia (CIN3) and cervical cancer, the HPV presence 
raises to almost 100% [61]. This observation was further exploited to identify HPV‐depen‐
dent‐specific biomarkers for cervical cancer detection.
Because the HPV genomes do not possess their own enzymes necessary for viral replication, 
these viruses will use the enzymatic machinery of the host infected cells (basal layer of squa‐
mous epithelia) to sustain DNA viral replication. HPVs possess small genomes, of about 8 kb 
in size, including a well‐conserved core set of genes involved in replication (E1 and E2) and 
packaging (L1 and L2). The remaining HPV genome includes genes (E4, E5, E6, and E7) that 
modify cellular environment, cell cycle regulation, immune evasion, and virus release. The 
detailed roles of the proteins encoded by these genes, involving host cells infection, evad‐
ing the immune system and the modulation of carcinogenic pathways were recently pre‐
sented [59]. Shortly, following infection, HPVs have the ability to insert their genetic material 
into host’s cell genome, leading to expression and replication of viral DNA by the host cell. 
Expression of viral genes E1 and E2 leads to the production of oncoproteins E5, E6, E7. These 
oncoproteins act in a cooperative way to promote malignant transformation of the host cell by 
inhibiting p53 and pRB tumor suppressor proteins, altering the apoptosis and the cell‐cycle 
control, activating telomerase and promoting the proliferation of infected cells.
Cellular changes due to HR‐HPVs are also visible in microRNA regulation. Several studies 
reported aberrant miRNA expression profiles in HPV positive cervical cancer when compared 
to HPV‐negative cervical cancers. In particular, E6 and E7, but also E5 HR‐HPV oncoproteins, 
are capable of modulating the expression of different miRNAs in host infected cervical cancer 
cells (Figure 3).
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In a study comprising 101 cervical cancer cases, Liu et al. [62] identified the E6 and E7 HPV 
transcripts in all the HPV‐positive cases (86% of all cervical cancer samples). Four miRNAs, 
including miR‐9, miR‐205, miR‐224 (up‐regulated) and miR‐29b (down‐regulated), were 
correlated with HP‐positive expression using HPV‐negative cancers as controls. MiR‐9 was 
selected for further investigations and validation as it was the most aberrantly expressed 
miRNA. Their results showed that miR‐9 is mostly expressed by HPV16 infected cells, and 
it is mainly activated by E6, (up‐regulated 45‐fold as a result of E6 expression), but also due 
to E7 (5‐fold up‐regulation). Based on target prediction algorithms, RNA‐seq data and RT‐
PCR experiments, they identified FASTL1 (involved in cellular proliferation) and ALCAM 
(involved in cell migration) as miR‐9 targets in cervical cancer.
Au Yeung et al. [63] demonstrated in vitro that HPV16 E6 protein leads to the down‐regula‐
tion of tumor suppressor miR‐23b, through p53 degradation. The decreasing expression of 
Figure 3. miRNAs modulated by HR‐HPV E5, E6 and E7 oncoproteins in cervical cancer. After infecting the basal layer of 
squamous epithelia, HPV virus modifies the cellular environment, cell cycle regulation, cell proliferation and migration, 
immune evasion and altering the apoptosis by regulation of specific miRNAs. HPVs insert their genetic material into 
host’s cell genome, leading to expression of specific sets of oncomiRs and blocking or modulating certain miRNAs, in a 
cooperative way that promote malignant transformation of the host cell.
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miR‐23b results in increasing expression of urokinase‐type plasminogen activator (uPA) that 
leads to increased migration of cervical tumor cells. Moreover, the reduce expression of miR‐
23b was related to invasion and metastasis, being considered a prognostic factor of cervical 
carcinoma [64].
In a similar study, Raver‐Shapira’s group [65] demonstrated that HPV E6 oncoprotein 
can decrease the expression of miR‐34a through p53 destabilization during viral infection. 
MiR‐34a represents an important tumor suppressor miRNA, whose alteration leads to cell 
proliferation, by activating the genes involved in cell cycle regulation such as cyclins (E2 and 
D1), cyclin‐dependent kinases (CDK4, CDK6), transcription factors (E2F1, E2F3, E2F5), and 
decreased apoptosis by up‐regulation of antiapoptotic Bcl‐2 [66, 67].
Another target of HPV16 E6 oncoprotein is miR‐218. In vitro and in vivo studies demonstrated 
that miR‐218 is down‐regulated by E6 oncoprotein in both precancerous lesions and cervical can‐
cers. In an in vivo study, Li’s group [68] proposed to investigate whether there is a correlation 
between HPV16 infection and miR‐218 down‐regulation and to evaluate the relationship between 
miR‐218 expression and CIN staging. Seventy‐eight CIN cases were included in this study. Of all 
the cases, 66% presented infection with a single HPV type, 24% presented infection with multiple 
HPV subtypes, and 9% were HPV free. Quantitative RT‐PCR measurements showed a down‐
regulation of miR‐218 in CIN cases presenting HR‐HPV infections compared to HPV‐free CIN 
cases. MiR‐218 expression levels dropped further down with CIN stage evolution, CIN3 cases 
presenting a significantly lower level of miR‐218 than CIN1. One of the targets of miR‐218 is 
LAMB3 with roles in cell migration and carcinogenesis of cervical cancer. Another study revealed 
that the expression of miR‐218 can lead to EMT inhibition, migration and invasion by targeting 
pro‐tumorigenic genes such as SFMBT1 and DCUN1D1 [69]. Recently, the expression of miR‐218 
in cervical cancer was associated with radiosensitivity via promoting radiation induced apopto‐
sis, down‐regulation of miR‐218 significantly reduced the radiation‐induced apoptosis [70].
If HR‐HPV E6 oncoprotein mediates the miRNAs targets through p53 destabilization, the HR‐
HPV E7 oncoprotein modulates the miRNAs targets by increasing the transcription of E2F 
family of transcription factors through degradation of pRB from pRB‐E2F complex, leading to 
releases and activation of transcription factor E2F [71]. In this regard, several miRNA targets 
of HR‐HPV E7 oncoprotein such as miR‐15a, miR‐15b and miR‐16 were identified as targets 
of E2F transcription factors [72, 73]. These miRNAs, considered tumor suppressor miRNAs 
(TS‐miRNAs), were identified as overexpressed in cervical cancers. Interestingly, miR‐15b 
was also suggested to play an important role in cervical carcinogenesis, regulating mecha‐
nisms such as angiogenesis, invasion and metastasis by targeting and down‐regulating the 
RECK gene, which can negatively affect the transcription and activity of MMPs [74]. Another 
target of E7 oncoprotein is represented by miR‐203, identified by Yi et al. [75]. Mir‐203, by its 
p63 target, has an important role in regulating the proliferation of undifferentiated basal cells 
and repress “stemness” of epithelial cells.
To identify new targets of HR‐HPV E6 and E7 oncoproteins, Wang et al. [76] established an 
in vitro study based on miR‐array and miR‐seq exploratory analysis, followed by data vali‐
dation on human samples. They identified in cell culture a set of 13 statistically significant 
miRNAs (miR‐16, miR‐25, miR‐92a, miR‐83, miRr‐106b, miR‐210, miR‐224, miR‐378, miR‐22, 
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miR‐24, miR‐27a, mR‐29a and miR‐100) specifically regulated by HR‐HPV E6 and E7 onco‐
proteins. Based on their preliminary data, eight miRNAs including miR‐16, miR‐22, miR‐25, 
miR‐27a, mR‐29a, miR‐92a, miR‐100 and miR‐378) were selected for further investigation, to 
determine which of the two E6 and E7 oncoproteins are their modulators.
HR‐HPV E7 oncoprotein had a stronger effect than HR‐HPV E6 oncoprotein on the positive 
regulation of miR‐25, miR‐378 and miR‐16, while both viral oncoproteins regulate a moderate 
overexpression of miR‐92a. The role of mir‐25 in cervical cancer is assigned to invasion and 
metastasis by negatively regulation of RECK gene [77], while miR‐16 by its CCNE1 target is 
involved in modulation of cell cycle progression [78].
Although miR‐378 was associated with cervical cancer, its precise role has not yet been speci‐
fied. Mir‐92a promotes cell proliferation and cell migration as well as apoptosis blocking by 
down‐regulation of PTEN [79]. The last four miRNAs investigated (miR‐22, miR‐27a, miR‐
29a and miR‐100) were down‐regulated by both E6 and E7 viral oncoproteins. While miR‐22 
inhibits tumor growth through a pro‐apoptotic effect by targeting ATP citrate lyase [80], 
down‐regulation of miR‐27a led to overexpression of B4GALT3 that mediates malignancies 
of cervical cancer by β1‐integrin pathway [81].
Cervical cancer progression is also mediated by the down‐regulation of miR‐29a resulting in 
HSP47 overexpression, which contributes to migration and invasion of cervical cancer [82], while 
down‐regulation of miR‐100 activates PLK1, increasing cell proliferation [83]. A common target 
of both E6 and E7 viral oncoproteins is miR‐129, with tumor suppressor activity. In cervical 
cancer, miR‐129 leads to up‐regulation of CDK6 and therefore to increasing cell proliferation by 
G1‐S cell cycle progression [84]. An important oncomir modulated by either E6 or E7 is miR‐155, 
found to have high expression, and also associated with poor prognosis in cervical cancers [40]. 
MiR‐155 is involved in proliferation of cervical tumor cells by down‐regulation of LKB1 tumor 
suppressor gene [85]. Recent evidence demonstrates that not only HR‐HPV E6 and E7 modu‐
late the miRNAs expression in cervical cancer, but also HR‐HPV E5 oncoprotein is involved 
in miRNAs targeting in cervical tumors. In a recent study, Liu et al. [86] demonstrated that E5 
viral oncoprotein can target and down‐regulate miR‐196a, leading to increasing proliferation 
and cell growth by expression of HOXB8 and reduce apoptosis by modulating the caspase 3/7. 
In another study, Greco et al. [87] showed that in HaCaT human keratinocytes transfected with 
HPV 16 E5 (HaCaT‐E5), the E5 oncoprotein can down‐regulate miR‐324‐5p and miR203 and can 
up‐regulate miR‐146a. While miR‐146 is involved in negative regulation of immune response in 
cervical cancer by targeting IRAK1 and TRAF6, miR‐324‐5p represents a negative modulator of 
the oncogenic Hedgehog pathway, contributing by its down‐regulation leading to carcinogen‐
esis and progression of cervical cancer. As we presented above, miR‐203 is also targeted by E7 
viral oncoprotein, being involved in epithelial cell differentiation and tumor progression [75].
4. MiRNAs expression in pre‐neoplasic lesions and cervical cancer
Similar to other cancers, miRNA profiling in cervical cancer tissues was a topic intensively 
studied. Different studies involving different designs, from comparing normal and cancer 
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tissues, primary and metastatic lesions, samples collected before and after surgery or therapy 
reported distinct miRNA profiles in cervical cancer.
There were studies, which used cervical cancer tissue and normal tissue samples from adja‐
cent spots. The normal tissues were harvested from spots located 2–5 cm beyond the bound‐
ary of the tumor of the same individual or from healthy individuals. Therefore, the cervical 
cancer samples and the normal tissue samples were very likely to have similar histological 
structures. Patients that were enrolled in these studies had not received chemo‐ or radiother‐
apy prior to sample collection, which in most cases, occurred during surgery. In this regard, 
Rao et al. [88] determined miRNA profiling of 26 matched cervical cancer and normal tis‐
sue samples collected from 13 patients. MiRNA gene expression of cervical cancer tissues 
and normal adjacent tissues was assessed using CaptialBio mammalian miRNA array V3.0 
(CapitalBio, Beijing, China). Microarray data analysis revealed that 18 miRNAs were signif‐
icantly up‐regulated and 19 miRNAs were significantly down‐regulated in cervical cancer 
tissue when compared to normal tissue (Table 2). Significant analysis of microarray (SAM) 
using false discovery rate (FDR) showed that the expression levels of the microRNAs identi‐
fied in this study were not dependent on lymph node metastasis (FDR = 0.529), vascular inva‐
sion (FDR = 0.371), or pathological differentiation (FDR = 0.163).
Author Up‐regulated  
miRNAs
Down‐regulated 
miRNAs
Samples/cell  
lines
Method Ref.
Rao et al. miR‐7, miR‐429, 
miR‐141, miR‐142‐5p, 
miR‐31, miR‐200a, 
miR‐224, miR‐20b, 
miR‐18a, miR‐200b, 
miR‐93, miR‐146b, 
miR‐200c, rno‐miR‐93, 
miR‐210, miR‐20a; 
PREDICTED_MIR189, 
rno‐miR‐31, 
rno‐miR‐93
miR‐127, rno‐
miR‐140, miR‐376a, 
miR‐214, miR‐218, 
miR‐1, miR‐368, 
miR‐145, miR‐100, 
miR‐99a, miR‐195, 
miR‐320, miR‐152, 
miR‐497, miR‐143, 
miR‐99b, miR‐10b, 
rno‐miR‐10b, 
mmu‐miR‐140
13 CC tissues/13 pair 
normal tissues
Microarray [88]
Shen et al. miR‐224 – 126 CC/126 pair 
normal tissues
qRT‐PCR [89]
Lui et al. miR‐21 let‐7b, let‐7c, 
miR‐23b, miR‐196b, 
miR‐143
Six cervical cell lines 
and 5 normal cervical 
tissues
Sequencing, 
Northern Blot
[90]
Han et al. miR‐21 – 30 CC tumor/30 
normal tissue
qRT‐PCR [91]
Ding et al. miR‐657, miR‐490‐5p, 
miR‐323‐3p
miR‐126, miR‐96, 
miR‐144
4 CC, PLN+/6 CC, 
PLN‐
Microarray 
qRT‐PCR
[92]
Cheung et al. miR‐518a, miR‐34b, 
miR‐34c, miR‐20b, 
miR‐338, miR‐9, 
miR‐512‐5p, miR‐424, 
miR‐345, miR‐10a
miR‐193b, miR‐203 24 CIN/9 healthy 
controls; validation 24 
CIN; cross validation 
51 CC
qRT‐PCR [93]
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Another comparative study on cervical cancer and normal tissue was performed by Shen’s 
group [89]. The qRT‐PCR results showed a higher expression of miR‐224. Moreover, miR‐224 
was significantly higher in advanced cervical cancers compared with early cervical cancers 
(p = 0.02) as well as in lymph node of metastatic‐positive patients compared with lymph node 
metastatic‐negative patients positive (p = 0.008), suggesting its role in cervical cancer progres‐
sion. Furthermore, miR‐224 was associated with less differentiated tumors (p = 0.03) and vascu‐
lar invasion (p = 0.01), being proposed as an independent prognostic marker of cervical cancer.
Lui et al. [90] adopted a sequencing approach to identify new miRNAs in six human cervical 
cancer cell lines when compared with five normal cervical tissues. Their results revealed six 
miRNAs statistically significantly expressed in cervical tumor cell lines compared to normal 
cervix (Table 2). Five out from these miRNAs, such as let‐7b, let‐7c, miR‐23b, miR‐196b and 
miR‐143, were down‐regulated, while miR‐21 was up‐regulated in cervical tumor cells. MiR‐21 
and miR‐143 were cross‐validated in a new set of 29 pairs of cervical cancers and their matched 
normal tissues. Both these miRNAs have confirmed higher, respectively, lower expressions 
when compared to normal cervical tissue, qualifying them as markers for cervical cancer.
Another approach was to assess single miRNAs in cervical cancer tissue samples as biomark‐
ers for diagnosis, and prognostic. In line with this view, Han et al. [91] compared the expres‐
sion levels of miR‐21 in 30 pairs of cervical cancer and normal tissue samples. Cervical tumor 
samples and normal tissue were collected from the same patients. The normal tissues were 
harvested beyond a 5 cm borderline from the tumor, in order to ensure the structure similarity 
between the tissue samples. MiR‐21 quantification by qRT‐PCR showed a higher expression 
level in cervical cancer tissues than in the normal ones with an average fold change of 4.02 and 
Author Up‐regulated  
miRNAs
Down‐regulated 
miRNAs
Samples/cell  
lines
Method Ref.
Ruiz et al. miR‐196a, miR‐18b, 
miR‐183, miR‐500, 
miR‐18a, miR‐25, 
miR‐182, miR‐20b, 
miR‐106a, miR‐20a
miR‐125b, 
miR‐10b, miR‐143, 
miR‐337‐5p, 
miR‐199a‐5p, 
miR‐199b‐3p, 
miR‐127‐3p, 
miR‐214, miR‐379, 
miR‐145
4 CC/4 healthy 
controls and 12 
tumoral cervical cell 
lines
Microarray [94]
Pereira et al. miR‐148a, miR‐302b, 
miR‐10a, miR‐196a, 
miR‐132
miR‐26a, miR‐29a, 
miR‐99a, miR‐143, 
miR‐145, miR‐199a 
miR‐203, miR‐513
19 normal tissue, 4 
squamous CC, 5 HSIL, 
9 LSIL
Microarray, 
qRT‐PCR
[95]
Li et al. miR‐155, miR‐92a mir‐29a, miR‐375, 
miR‐195, mir‐99a
51 CC, 51 CIN2/3, 
21HR‐HPV infected 
normal cervix, 49 
normal specimens
Microarray, 
qRT‐PCR
[96]
Abreviations: CC, cervical cancer; CIN, cervical intraepithelial neoplasia; HSIL, high‐grade squamous intraepithelial 
lesion; LSIL, low‐grade squamous intraepithelial lesion.
Table 2. MiRNAs expression in cervical cancer/CIN compared with normal tissues.
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p value <0.05. Moreover, miR‐21 up‐regulation was correlated with HPV16 infection by a rela‐
tive expression level of 2.37 in HPV16 positive cases and only 1.94 in HPV16 negative cases. 
MiR‐21 activity was also correlated with clinicopathological parameters including depth of 
invasion p = 0.031 and lymph node metastasis p = 0.015.
Ding et al. [92] reported a miR‐microarray analysis where they identified a specific miRNA pro‐
file for metastatic cancers (PLN‐positive) compared with non‐metastatic cases (PLN‐negative). 
Thirty‐nine miRNAs with FC > 4 were included in this molecular signature; 22 miRNAs were 
significantly up‐regulated, and 17 miRNAs were significantly down‐regulated in the PLN‐pos‐
itive group when compared with PLN‐negative group (Table 2). Six of these miRNAs includ‐
ing miR‐126, miR‐96, miR‐144, miR‐657, miR‐490‐5p and miR‐323‐3p for which were identified 
tumor associated putative target genes, involved in cell proliferation, apoptosis, tumor inva‐
sion and metastasis, were validated by qRT‐PCR. However, they suggested that their data have 
to be confirmed on larger studies before making a reliable hypothesis related to these miRNAs.
Another important approach was to identify miRNAs for early diagnosis of cervical cancer. 
Cheung et al. [93] tried to identify a specific miRNA signature for CIN and to reveal what miR‐
NAs could be involved in cervical carcinogenesis. Twenty‐four high‐grade cervical intraepi‐
thelial carcinoma (CIN 2/3) and nine normal cervical epithelium samples were used in a testing 
study for miRNA profiling, using qRT‐PCR method for screening the expression of 202 target 
miRNAs. The obtained results, a set of 12 miRNAs (Table 2) statistically significantly expressed 
(FC ≥ 2, p < 0.05) between CIN and normal tissue, were further validated in a validation set of 
24 high‐grade CIN samples. Because permutation analysis returned 0.0% FDR for this set of 
miRNAs, a new analysis on an independent cohort of 51 squamous cell carcinomas was pro‐
posed, to reveal the miRNAs associated with cervical carcinogenesis. The fold change values 
of up‐regulated miRNAs between CIN patients and normal subjects were ranging between 
2.07 and 3.53 and between 2.67 and 2.81 for down‐regulated ones. In the case of squamous cell 
carcinoma (SCC), seven miRNAs of 12 validated for CIN samples were identified as important 
for cancer progression. From these, miR‐9, miR‐20b, miR‐345, miR‐338, miR‐518a and miR‐
512‐5p were up‐regulated, and miR‐203 was down‐regulated in cervical cancers versus normal 
epithelium control. Consequently, a specific miRNA signature that can distinguish CIN and 
cervical tumors from normal cervical epithelium was proposed. In the same line, Ruiz’s group 
[94] used a microarray approach to identify differentially expressed miRNAs in cervical cancer 
cell lines as well as in cervical cancer and normal tissues. They studied miRNA expression on 
12 cervical cancer cell lines, four cervical cancer tumor tissues and four normal tissue samples. 
They identified a set of miRNAs with significantly abnormal expression, of which, miR‐196a 
had the highest expression level for cervical cancer tissues (p = 4.75E−04) and cancer cell lines 
(p = 1.32E−07). Up‐regulation of miR‐196a was confirmed by qRT‐PCR analysis in cervical 
cancer tissues, low‐grade squamous intraepithelial lesion (LSIL) and high‐grade squamous 
intraepithelial lesion (HSIL) and cervical cancer cell lines. A highest up‐regulation of miR‐196a 
was observed in cervical cancer cell lines and a slight up‐regulation in cervical cancer tissues. 
Other 19 miRNAs were found statistically significantly expressed in microarray analysis; nine 
of them were up‐regulated, while the rest of 10 were down‐regulated (Table 2).
Pereira et al. [95] profiled miRNA expression in a heterogenous set of 25 cervical tissues includ‐
ing 19 normal cervical tissue, four squamous cervical carcinoma, five high‐grade squamous 
Colposcopy and Cervical Pathology124
intraepithelial lesions (HSILs) and nine low‐grade squamous intraepithelial lesions (LSILs). 
MiRNA profiling revealed a high variability of their expression among normal samples and a 
lack of clear separation of normal, pre‐neoplasic and cervical cancer samples. One of the reasons 
claimed by authors was related to the fact that a part of normal cervical epitheliums harvested 
from area adjacent to the tumors were HPV infected. However, they identified two sets of statisti‐
cally up‐regulated and down‐regulated miRNAs between precancerous and cancerous samples 
when compared with normal cervical tissues. Eight down‐regulated miRNAs including miR‐
26a, miR‐29a, miR‐99a, miR‐143, miR‐145, miR‐199a miR‐203, miR‐513 and five overexpressed 
miRNAs including miR‐148a, miR‐302b, miR‐10a, miR‐196a and miR‐132 were associated with 
transition from normal cervix to both precancerous stages (atypical dysplasia) and cancer.
Ly et al. [96] profiled miRNA‐microarray expression in six HPV16‐positive cervical can‐
cers, six HPV16‐positive intraepithelial neopasia (CIN2/3) and six normal cervix tissues. 
They identified a set of 31 statistically significant miRNAs that distinguish cervical tumors 
from precancerous and normal samples. Six miRNAs (miR‐155, miR‐92a mir‐29a, miR‐375, 
miR‐195 and miR‐99a) were further successfully validated in a panel of 91 samples including 
24 HPV16‐positive cervical cancers, 24 HPV 16‐positive CIN2/3 and 43 normal cervical tis‐
sues. Considering that cervical cells can be infected by different HR‐HPV not only by HPV16, 
they also investigated and validated the expression of these six miRNAs in a larger group of 
45 HR‐HPV + cervical cancer, 45 HR‐HPV + CIN2/3 and 43 normal cervical tissues.
5. MiRNAs expression in serum of patients with pre‐neoplasic lesions 
and cervical cancer
Due to their high stability in easy accessible body fluids and their proved differential expres‐
sion between cervical cancer and normal tissue, miRNAs have arisen as potential biomarkers 
for diagnosis and prediction of this disease.
In this regards, Jia et al. [97] performed a sequencing experiment to identify specific miRNAs in 
the serum of cervical cancer patients and normal subjects. They identified a set of 12 miRNAs 
differentially expressed between two groups. Cross‐validation on a second set of 103 patients 
and 74 controls confirmed the significant up‐regulation of five microRNAs (miR‐21, mIR‐29a, 
miR‐200a, miR‐25 and miR‐486‐5p) in cervical cancer when compared to the negative controls. 
MiR‐21, one of the highest up‐regulated microRNAs, was previously reported as overexpressed 
in cervical tumors, being an oncomir associated with poor prognosis [90, 91]. The diagnostic 
value of selected miRNAs was assessed by ROC analysis, showing that with each subsequent 
miR addition, the biomarker panel gained a higher sensitivity and specificity in discriminating 
cervical cancer from controls. With an AUC value of 0.908 (95% CI: 0.868–0.948), these results 
suggest the potential of the five microRNAs as noninvasive markers in cervical cancer.
Serum miRNAs could become valuable prognostic biomarkers (Table 3), aiding clinicians 
in treatment decision, to distinguish between cases that could be treated by using the classic 
therapy and the ones that might need a different approach because of a higher risk of develop‐
ing lymph node metastasis.
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Author Serum 
microRNAs
Cases Technology Validation/cross 
validation
Test accuracy Ref.
Jia et al. ↑miR‐21
↑miR‐29a
↑miR‐200a
↑miR‐25
↑miR‐486‐5p
213 CC 
patients
158 controls
Solexa 
sequencing
qRT‐PCR
103 patients
74 controls
CC vs. healthy
AUC 0.908; 95% 
CI: 0.868‐0.948; 
sensitivity: 81.0%, 
specificity 88.6%
[97]
Chen et al. ↑miR‐205 60 CC 
patients60 
controls
qRT‐PCR Same subjects 
60 CC60 
controls
LN+ vs LN−
0.694; sensitivity: 
71.1%, specificity: 
72.7% moderately 
differentiated vs 
poorly differetiated 
0.717; sensitivity: 
76.5%, a specificity: 
73.1%
[98]
Zhao et al. ↑miR‐1246
↑miR‐20a
↑miR‐2392
↑miR‐3147
↑miR‐3162‐5p
↑miR‐4484
40 CC LN+
40 CC LN−
20 controls
Microarray 
qRT‐PCR
– LN+ vs LN−
AUC 0.932; 95% 
CI: 0.884‐0.980, 
sensitivity 0.856, 
specificity 0.850
[99]
Ma et al. ↑miR‐20a
↑miR‐203
40 CC LN+
40 CC LN−
20 controls
qRT‐PCR – miR‐20a LN+ vs 
LN−
AUC 0.734; 95% 
CI: 1.137–2.118, 
sensitivity: 75%, 
specificity: 72.5%
miR‐203 LN+ 
vsLN−
AUC 0.658; 
sensitivity: 65%, 
specificity: 62.5%
[100]
Yu et al. ↓miR‐218 90 CC
50 controls
qRT‐PCR – cc vs normal 
expression levels
1.000 vs 0.392
LN+ vs LN− 
expression levels
0.235 vs 0.468
[101]
Zhang et al. ↑miR‐16‐2
↑miR‐497
↑miR‐2861
↓miR‐195
184 CC 
patients 186 
CIN
193 controls
qRT‐PCR 85 CC
91 CIN
93 controls
CC vs healthy
AUC 0.849; 95% 
CI: 0.813–0.886; 
sensitivity: 73.1%, 
specificity: 88.4%
CC vs CIN
AUC 0.829; 95% 
CI: 0.794–0.865; 
sensitivity: 71.4%, 
specificity: 67.2%
cin vs healthy
AUC 0.734; 95% 
CI, 0.683‐0.784; 
sensitivity: 62.6%, 
specificity: 88.9%
[102]
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Using microarrays screening tools, Chen et al. [98] identified 89 miRNAs that had different 
expressions both in serum and in tissue samples of positive lymph node metastasis cervical 
cancer patients when compared to healthy controls. For further analysis, they restricted the 
number of microRNAs of interest, by choosing the microRNAs with the highest expression 
levels that are presented in both serum and tissue samples. They identified a six‐miRNA 
panel (miR‐1246, miR‐20a, miR‐2392, miR‐3147, miR‐3162‐5p and miR‐4484) with a diagnostic 
value for lymph node metastasis in cervical cancer patients, having a sensitivity of 0.856 and 
a specificity of 0.850.
Consistent cervical cancer serum levels of miR‐20a were reported by Zhao et al. [99]. miR‐20a 
being significantly up‐regulated in serum samples collected from females with cervical cancer 
stages I–IIA, when compared to healthy donors. Moreover, higher differences were reported 
in serum samples from patients with positive lymph node metastasis (LN+) than in the ones 
without lymph node metastasis (LN−). They showed that miR‐20a expression level could 
be used as a lymph node metastasis diagnosis tool, distinguishing LN+ from LN− patients 
with a moderate accuracy (AUC = 0.734) the test having a sensitivity of 75%, and a specificity 
of 72.5%. They also measured the expression level of miR‐203 in serum samples of cervical 
cancer patients and healthy donors. Although it was observed a significant up‐regulation of 
serum miR‐203 in cervical cancer patients, miR‐203 showed a low accuracy for distinguishing 
LN+ from LN− patients.
Ma’s group [100] measured miR‐205 level in blood and tissue samples of cervical can‐
cer patients and paired healthy controls. They found a fivefold up‐regulation of miR‐205 
in serum from cervical cancer patients, comparing to normal, and threefold up‐regulation 
in tissue samples. Moreover, a higher expression level of miR‐205 was correlated with an 
advanced cancer stage, a worse overall survival rate, and metastasis. As a prognosis bio‐
marker, miR‐205 expression level could differentiate between metastatic and non‐metastatic 
cases with a sensitivity of 71.1% and specificity of 72.7%, and distinguish poorly differenti‐
ated tumors from that moderately differentiated ones with a sensitivity of 76.5% and a speci‐
ficity of 73.1%.
Author Serum 
microRNAs
Cases Technology Validation/cross 
validation
Test accuracy Ref.
Nagamitsu 
et al.
↑miR‐1920 70 CC patients
55 CIN
31 controls
Microarray 
qRT‐PCR
45 CC patients
55 CIN
31 controls
CC vs 
healthy0.7957; 95% 
CI: 0.6937‐0.8977; 
sensitivity: 90.3%, 
specificity: 62.2%,
[103]
Liu et al. ↑miR‐196a 105 CC 
patients
86 CIN
50 controls
qRT‐PCR – – [104]
Abbreviations: CC, cervical cancer; CIN, cervical intraepithelial neoplasia; LN+, lymph node positive; LN−, lymph node 
negative; AUC, area under curve.
Table 3. MiRNAs expression in serum serum of patients with pre‐neoplasic lesions and cervical cancer.
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Yu’s group [101] investigated if serum miR‐218 can be associated with cervical cancer. 
Accordingly, they identified reduced level of miR‐218 in serum samples of 90 cervical cancer 
patients (expression level 0.392 ± 0.021) when compared to 50 healthy controls (expression 
level 1.000 ± 0.062). Quantitative RT‐PCR showed even more decreasing levels of miR‐218 
in cervical cancer patients with advanced stages (0.128 ± 0.016) compared to earlier ones 
(0.425 ± 0.033). Moreover, they observed the same tendency for those patients presenting 
lymph node metastasis (0.235 ± 0.020) compared to non‐metastatic cases (0.468 ± 0.018), and 
it suggested that miR‐218 could represent a marker for prognosis. An interesting observa‐
tion was that miR‐218 expression level was lower for adenocarcinoma (0.216 ± 0.016) than for 
squamous cell cervical cancer (0.399 ± 0.019).
Timely biomarker detection would be of a great importance, considering the increased chances 
of survival and lower recurrence rates at early stages. Also, a blood‐based biomarker that has 
a comparable or higher sensitivity and specificity than Pap test would be of a great benefit 
especially in the areas where high‐quality medical care and screening are not available.
In line with this view, Zhang et al. [102] performed a qRT‐PCR‐based screening study evaluat‐
ing the performance of circulating miRNAs as diagnostic biomarkers in the serum of patients 
with cervical cancer and patients with CIN. The study followed a multi‐step approach: 
screening, testing and validation. For validation, they used randomly selected cervical cancer 
patients, CIN subjects and healthy individuals as negative controls. MirRNAs identified in 
the first cohort of patients in the screening step were tested in a second cohort and finally 
cross‐validated on a third group of patients. A panel of four miRNAs (miR‐16‐2, miR‐497, 
miR‐2861, miR‐195) with significantly aberrant expression was selected to discriminate cervi‐
cal cancer from healthy subjects (AUC: 0.849; 95% CI: 0.813–0.886; sensitivity: 73.1%, specific‐
ity: 88.4%) and CIN (AUC: 0.829; 95% CI: 0.794–0.865; sensitivity: 71.4%, specificity: 67.2%). 
This 4‐miRNA signature also distinguishes CIN from healthy subjects (AUC: 0.734; 95% CI: 
0.683–0.784; sensitivity: 62.6%, specificity: 88.9%).
Following a similar workflow, Nagamitsu et al. [103] reported a recent microarray study that 
identified a panel of four up‐regulated miRNAs (miR‐485‐5p, miR‐1246, miR‐1275, miR‐1290) 
in the serum of cervical cancer patients. Mir‐1290 was particularly up‐regulated, so the group 
further investigated its expression level in the sera of CIN individuals and cervical cancer 
patients at different stages. The results showed that miR‐1290 levels could differentiate cervi‐
cal cancer patients from healthy subjects with an AUC value of 0.7957 (95% CI: 0.6937–0.8977; 
sensitivity: 90.3%; specificity: 62.2%). Also, miR‐1290 up‐regulation was correlated with can‐
cer progression, with lowest expression in the control group and gradually increased expres‐
sion from CIN2 to locally advanced cervical cancers, showing biomarker potential for cervical 
cancer diagnosis in early stages.
In another study, Liu’s group [104] evaluated the expression of serum miR‐196a in 105 cer‐
vical cancer patients, 85 CIN individuals and 50 healthy subjects. Their data revealed a sig‐
nificantly higher relative expression level of miR‐196a in cervical cancer patients than in both 
healthy and CIN individuals, and higher expression in CIN than in healthy subjects. The 
study aimed to identify the clinical significance of serum miR‐196a in cervical cancer and CIN 
patients. Their results showed an association between miR‐196a and clinical parameters of 
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cervical cancer patients, such as tumor size, lymph node (LN) metastasis, FIGO stage and can‐
cer grade, but no association with HPV infection, age, or cell type. Also, they observed differ‐
ent levels of miR‐196a expression depending on CIN grade, with a lower expression in CINI 
and CINII and a significantly higher expression level in CINIII. Moreover, overall survival 
of cervical cancer patients was negatively correlated with higher miR‐196a expression. These 
results suggest that serum miR‐196a could represent a reliable biomarker for early diagnosis 
and prognosis of cervical cancer.
6. MiRNAs expression in exfoliated cells of cervix
In addition to cervical cancer screening tests by using serum‐based diagnosis biomarkers, in a 
recent study, Tian et al. [105] have approached a new screening method for early detection of 
cervical cancer. This group collected residual exfoliated cell samples from HPV‐positive sub‐
jects that underwent Pap test. Samples were triaged by Pap test and colposcopy in six groups, 
depending on the lesions grade, ranging from normal to ASCUS, LSIL, ASC‐H, HSIL, and 
finally CC. Sampled cells from 1021 HPV‐positive women were used for measuring the expres‐
sion levels of several microRNAs, which were previously detected as abnormally regulated 
in cervical cancer (miR‐424/miR‐375/miR‐34a/miR‐218/miR‐92a/miR‐93). Detailed cytologi‐
cal examination classified the subjects by CIN grade. Quantitative RT‐PCR analysis showed 
that relative expression levels of miR‐218, miR‐34a, miR‐424 and miR‐375 were significantly 
lower in more advanced CIN grades (CIN2+ and CIN3+) than in the incipient ones (CIN‐1 and 
CIN‐2), suggesting that those microRNAs could be used as candidate biomarkers in cervical 
cancer screening. For determining the diagnosis value, the group performed ROC analysis 
for miR‐424, miR‐375, miR‐34a and miR‐218 and compared them to the ROC curve for Pap 
test. Both miR‐424 and miR‐375 detection in cervical exfoliated cells had a greater AUC (0.828 
for miR‐424 and 0.760 for miR‐375) and a higher sensitivity (82.3% for miR‐424 and 80.9% for 
miR‐375, respectively) and specificity (70% for miR‐424 and 71.2% for miR‐375, respectively) 
in identifying high‐grade CIN (CIN3+) than Pap test (AUC: 0.699; sensitivity 69.8%, specificity 
70%). A lower performance was registered for miR‐34 and miR‐218. In conclusion, this study 
opens future challenges in non‐invasive diagnosis procedures. MicroRNA detection in cervi‐
cal exfoliated cells could be an effective option for triage of HPV‐positive women and incipient 
cancer detection, especially for those areas where well‐trained cytologists are lacking.
7. MiRNAs modulate treatment response in cervical cancer
The molecular mechanisms of resistance to radiation in cervical cancer are not well under‐
stood. The discovery of miRNAs opened the opportunity to research for new molecules that 
mediate treatment response, with potential to be developed into new targeting strategies and/
or prediction algorithms in cervical cancer treatment. However, the current knowledge is still 
limited, and there are just a few reports describing the role of miRNAs as modulators of treat‐
ment response in cervical cancer.
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In a recent study, Song et al. [106] investigated the role of miR‐375 in radiotherapy resistance 
in HR‐HPV‐positive cervical cancers. They evaluated tissue and serum expression of miR‐375 
in both cervical cancer patients (n = 22) and healthy control subjects (n = 20) highlighting sig‐
nificantly down‐regulated expression also in tissue (p < 0.001) and serum (p < 0.001) of can‐
cer patients when compared to normal individuals. The authors also assessed the miR‐375 
expression level in serum and tissue samples at 6 months after completion of the radiotherapy 
treatment and correlated its expression with clinical and histological data. Their data showed 
low expression of miR‐375 in tissue (p < 0.001) and serum (p < 0.001) of radioresistant patients 
when compared with radiosensitive patients. Further investigations have proved that miR‐375 
may induce radioresistance in cervical cancer cells by targeting UBE3A and BIRC5 (surviving) 
and regulate apoptosis through the 53 pathway.
Ye et al. [107] reported decreased miR‐145 expression in tumors and cervical cell lines when 
compared with cervical non‐tumor tissue and normal cell lines. Five potential targets of 
miR‐145 including HLTF, CUT2, BCR, BUFIP2 and ZCH11A were identified by in silico 
analysis, but only HLTFs were further investigated due to its mRNA highest expression 
(1.96‐fold). The expression of HLTF was higher in cervical tumors than in normal tissues and 
significantly negatively correlated with miR‐145 in cervical cancers. Moreover, performing 
luciferase reporting assay, this group has proved that HTLF is a specific target of miR‐145. 
HTLF influences the outcome of radiotherapy in cervical tumors playing an important role in 
chromatin remodeling and enhancing DNA damage repair capacity of cervical tumor cells, 
therefore miR‐145 down‐regulation could lead to radioresistance in cervical cancers.
Ke et al. [108] investigated the role of miR‐181a in radiotherapy resistance of cervical cancers. 
MiRNA microarray profiling in seven radio‐resistant cervical samples and 11 radio‐sensi‐
tive cervical tumors led to the identification of eight miRNAs (miR‐181a, miR‐21, miR‐30, 
miR‐23a, miR‐16‐2, miR‐378, miR‐18a and miR‐221) significantly expressed between groups. 
Further investigation showed that miR‐181a has no effect on cell proliferation but lead to inhi‐
bition of apoptosis by targeting the PRKCD gene and decreasing the caspase 3/7 activity. The 
authors suggested that miR‐181a protects cervical tumor cells from radiation‐inducing death 
by inhibiting of apoptosis.
8. Conclusion
Data presented above provide evidences that miRNAs modulated by HR‐HPV E5, E6 and E7 
oncoproteins could be investigated as potential biomarkers for early diagnosis of pre‐neo‐
plasic and neoplasic lesions of the cervix. Moreover, miRNAs identified in serum and exfo‐
liated cervical cells could be taken into account as valuable minimal invasive markers for 
monitoring cervical cancer progression and its treatment response.
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